Voya Investment Management LLC raised its holdings in LifeStance Health Group, Inc. (NASDAQ:LFST - Free Report) by 1,249.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,971,989 shares of the company's stock after buying an additional 3,677,679 shares during the period. Voya Investment Management LLC owned about 1.04% of LifeStance Health Group worth $47,783,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds have also added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in shares of LifeStance Health Group in the second quarter worth approximately $389,293,000. Dimensional Fund Advisors LP boosted its position in shares of LifeStance Health Group by 16.4% during the first quarter. Dimensional Fund Advisors LP now owns 10,367,680 shares of the company's stock valued at $66,038,000 after buying an additional 1,461,215 shares during the last quarter. Wellington Management Group LLP bought a new stake in LifeStance Health Group during the second quarter worth $30,881,000. Bank of America Corp DE grew its holdings in LifeStance Health Group by 165.0% during the first quarter. Bank of America Corp DE now owns 1,994,027 shares of the company's stock worth $12,702,000 after buying an additional 1,241,475 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in LifeStance Health Group during the second quarter worth $11,626,000. Institutional investors and hedge funds own 85.50% of the company's stock.
Analyst Ratings Changes
A number of research analysts recently weighed in on LFST shares. JPMorgan Chase & Co. raised their price target on shares of LifeStance Health Group from $13.00 to $15.00 and gave the company a "neutral" rating in a research report on Thursday, November 12th. Wall Street Zen raised shares of LifeStance Health Group from a "buy" rating to a "strong-buy" rating in a report on Saturday, November 14th. Canaccord Genuity Group lifted their target price on LifeStance Health Group from $15.00 to $16.00 and gave the company a "buy" rating in a report on Friday, November 6th. Weiss Ratings reissued a "hold (c)" rating on shares of LifeStance Health Group in a report on Wednesday, November 4th. Finally, BTIG Research raised their price target on LifeStance Health Group from $18.00 to $20.00 and gave the stock a "buy" rating in a research report on Thursday, November 5th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $14.86.
Read Our Latest Report on LFST
Insider Activity
In other news, COO Lisa Miller sold 14,663 shares of the company's stock in a transaction dated Wednesday, November 11th. The stock was sold at an average price of $14.68, for a total value of $215,252.84. Following the completion of the transaction, the chief operating officer owned 251,904 shares of the company's stock, valued at $3,697,950.72. This represents a 5.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Ryan Pardo sold 2,216,585 shares of LifeStance Health Group stock in a transaction that occurred on Tuesday, November 10th. The shares were sold at an average price of $14.58, for a total transaction of $32,317,809.30. Following the sale, the insider owned 334,935 shares in the company, valued at approximately $4,883,352.30. The trade was a 86.87% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 2,861,235 shares of company stock worth $41,646,338 over the last ninety days. Corporate insiders own 3.50% of the company's stock.
LifeStance Health Group Stock Down 3.1%
LifeStance Health Group stock opened at $13.34 on Friday. The firm has a market cap of $5.07 billion, a price-to-earnings ratio of 70.21 and a beta of 1.35. The stock has a fifty day simple moving average of $12.88 and a two-hundred day simple moving average of $9.81. LifeStance Health Group, Inc. has a 12 month low of $6.09 and a 12 month high of $15.66. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 0.17.
LifeStance Health Group (NASDAQ:LFST - Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.02. LifeStance Health Group had a net margin of 4.29% and a return on equity of 4.82%. The firm had revenue of $455.86 million during the quarter, compared to analysts' expectations of $431.59 million. LifeStance Health Group's revenue was up 25.3% compared to the same quarter last year. Equities analysts predict that LifeStance Health Group, Inc. will post 0.20 EPS for the current fiscal year.
About LifeStance Health Group
(
Free Report)
LifeStance Health Group, Inc. is a U.S. provider of outpatient mental health services. The company offers care through in-person clinics and virtual appointments, connecting patients with behavioral health professionals. Its services include psychotherapy, psychiatric evaluations and medication management. LifeStance's clinicians treat a range of mental health conditions, including anxiety, depression, attention-deficit/hyperactivity disorder and mood disorders. Founded in 2017, LifeStance has expanded its network across the United States.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider LifeStance Health Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LifeStance Health Group wasn't on the list.
While LifeStance Health Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.